Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

JOURNAL ARTICLE published July 2021 in The Lancet Oncology

Authors: Arjun V Balar | Ashish M Kamat | Girish S Kulkarni | Edward M Uchio | Joost L Boormans | Mathieu Roumiguié | Laurence E M Krieger | Eric A Singer | Dean F Bajorin | Petros Grivas | Ho Kyung Seo | Hiroyuki Nishiyama | Badrinath R Konety | Haojie Li | Kijoeng Nam | Ekta Kapadia | Tara Frenkl | Ronald de Wit